Connecticut Innovations, the state’s venture capital investment arm, invested $7.2 million in startups in the second quarter of fiscal 2021.
The investments were made across 26 transactions, according to CI. The venture fund invested about $2.3 million in IT companies, and $4.3 million in startups within the bioscience and health care information technology spaces, CI said. CI spent the rest of the money on companies in varying industries.
CI’s largest investments in the quarter, which ended Dec. 31, went to Artizan Biosciences, DiA Imaging Analysis, IsoPlexis and Payveris.
CI’s investments for fiscal 2021’s second quarter include:
- 1843 Capital, LLC, Greenwich: $3,802
- Artizan Biosciences, New Haven: $1,000,000
- Athena Therapeutics, New Haven: $150,000
- CiDRA Holdings, LLCÂ Â Â Wallingford: $500,000
- CoreChain, New Haven: $100,000
- Curacity, Stamford: $350,000
- DiA Imaging Analysis, New Haven: $1,000,000
- HighCape Partners, Westport: $105,000
- IsoPlexis, Inc., Branford: $1,000,000
- KovaDX, New Haven: $15,000
- Landsdowne Labs, Fairfield: $125,000
- LindaCare, Hartford: $335,182
- LYMBR, Norwalk: $15,188
- PayVeris LLC, Cromwell: $1,100,000
- Realty Automation Labs, Guilford: $100,000
- RevMedica, Durham: $50,000.00Â
- ServiceInsight, Madison: $150,000
- Smart Seal, Hartford: $100,000
- Statera Therapeutics, New Haven: $15,000
- University of Connecticut Health Center, Farmington: $150,000
- Veradermics, West Hartford: $15,000
- Veradermics, West Hartford: $15,000
- Veradermics, West Hartford: $116,000
- Yale University School of Medicine, New Haven: $150,000
- Yale University School of Medicine, New Haven: $60,000
- Zorus, Monroe: $500,000
Â
